<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03568396</url>
  </required_header>
  <id_info>
    <org_study_id>RIPH3-RNI18-DOLOCEC</org_study_id>
    <secondary_id>2018-A01137-48</secondary_id>
    <secondary_id>28/18_3</secondary_id>
    <nct_id>NCT03568396</nct_id>
  </id_info>
  <brief_title>Validation of Pupillary Response to Nociceptive Stimulation in Cardiac Surgery During Extracorporeal Circulation Period</brief_title>
  <acronym>DOLOCEC</acronym>
  <official_title>Validation of Pupillary Response to Nociceptive Stimulation in Cardiac Surgery During Extracorporeal Circulation Period</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Tours</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Tours</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The relationship between the target effect site concentration of remifentanil and the pupil&#xD;
      diameter and reactivity in response to a standard noxious stimulus in cardiac surgery during&#xD;
      extra corporeal circulation will be evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anaesthesia will be induced with propofol to obtain loss of consciousness LOC in 30 patients&#xD;
      who will undergo cardiac surgery requiring extracorporeal circulation and standardized&#xD;
      support will be given to them till the extracorporeal circulation period. Thereafter,&#xD;
      remifentanil will be titrated by increments of 0,5, from 1 up to 5 ng ml-1 during the extra&#xD;
      corporeal circulation period. In the awake state, at LOC and at each plateau level of&#xD;
      remifentanil CeT, mean arterial pressure, and BIS will be recorded. Pupil size and dilatation&#xD;
      after a 60 mA, 100 Hz tetanic stimulation will be measured at LOC and at each plateau level&#xD;
      of remifentanil.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 22, 2018</start_date>
  <completion_date type="Actual">October 25, 2018</completion_date>
  <primary_completion_date type="Actual">October 25, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validation the use of pupillometry as a method of evaluation of nociception in cardiac surgery during the extracorporeal circulation period.</measure>
    <time_frame>During surgery / one day</time_frame>
    <description>To prove the existence of a linear correlation between the change in pupillary diameter and the concentration of remifentanil in cardiac surgery during the extracorporeal circulation period</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Validity of pupillometry nociception measurements in moderate hypothermia</measure>
    <time_frame>During surgery / one day</time_frame>
    <description>To prove existence of a linear correlation between the change in pupillary diameter and the remifentanil concentration in moderate hypothermia.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Comparison of changes in mean arterial pressure and bispectral index to changes in pupillary diameter</measure>
    <time_frame>During surgery / one day</time_frame>
    <description>Compare changes in mean arterial pressure and bispectral index at the time of nociceptive stimulus with changes in pupillary diameter</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">30</enrollment>
  <condition>Pupil</condition>
  <condition>Analgesics</condition>
  <condition>Opioid Use</condition>
  <condition>Dose-Response Relationship, Drug</condition>
  <condition>Anesthetics, Intravenous</condition>
  <condition>Surgery, Cardiac</condition>
  <condition>Circulation, Extracorporeal</condition>
  <condition>Electric Stimulation</condition>
  <condition>Electroencephalography/Drug Effects</condition>
  <condition>Monitoring, Intraoperative</condition>
  <condition>Adult</condition>
  <condition>Remifentanil</condition>
  <arm_group>
    <arm_group_label>Pupillometry</arm_group_label>
    <description>The relationship between the target effect site concentration of remifentanil and the pupil diameter and reactivity in response to a standard noxious stimulus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Pupillometer</intervention_name>
    <description>Measurement of pupil diameter and reactivity in response to a standard noxious stimulus in cardiac surgery during extracorporeal circulation period.</description>
    <arm_group_label>Pupillometry</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients consulting for a general anesthesia for cardiac surgery programmed requiring the&#xD;
        realization of a sternotomy and the use of extra corporeal circulation&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  general anesthesia for cardiac surgery programmed requiring the realization of a&#xD;
             sternotomy and the use of extra corporeal circulation&#xD;
&#xD;
          -  age&gt; 18 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindication to the use of the products defined in the protocol of anesthesia&#xD;
             (alprazolam, remifentanil, propofol, atracurium)&#xD;
&#xD;
          -  sedation in progress with use of morphinomimetics&#xD;
&#xD;
          -  urgent surgery&#xD;
&#xD;
          -  preoperative existence of circulatory assistance&#xD;
&#xD;
          -  preoperative existence of an intra-aortic balloon pump,&#xD;
&#xD;
          -  bilateral ocular pathology (severe cataract, amblyopia, glaucoma, keratitis,&#xD;
             conjunctivitis) and / or history of bilateral ocular surgery affecting the iris&#xD;
&#xD;
          -  history of epilepsy, cerebral palsy&#xD;
&#xD;
          -  peripheral neuromuscular diseases&#xD;
&#xD;
          -  pathology with dysautonomia impairing the pupillary dilation reflex: insulin-dependent&#xD;
             type 1 or type 2 diabetes with diabetic retinopathy, multiple sclerosis, systemic&#xD;
             amyloidosis, uncontrolled hypertension, advanced Parkinson's disease&#xD;
&#xD;
          -  ongoing treatment interfering with the autonomic and central nervous system likely to&#xD;
             alter the pupillary dilation reflex: antiemetic (droperidol, metoclopramide), alpha-2&#xD;
             agonist (clonidine, dexmedetomidine), high doses of nitrous oxide&#xD;
&#xD;
          -  treatment with severe anticholinergic effect: such as amitriptyline, amoxapine,&#xD;
             atropine, benztropine, chlorpheniramine, chlorpromazine, clemastine, clomipramine,&#xD;
             clozapine, darifenacin, desipramine, dicyclomine, diphenhydramine, doxepin, flavoxate,&#xD;
             hydroxyzine, hyoscyamine, imipramine, meclizine, nortriptyline, orphenadrine,&#xD;
             oxybutynin, paroxetine, perphenazine, procyclidine, promazine, promethazine,&#xD;
             propentheline, pyrilamine, scopolamine, thioridazine, tolterodine, trifluoperazine,&#xD;
             trihexyphenidyl, trimipramine&#xD;
&#xD;
          -  pregnant or lactating women&#xD;
&#xD;
          -  Patient having objected to the processing of his data&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fabien ESPITALIER, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Tours</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Location Anesthesia-Resuscitation Department, University Hospital, Tours</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 26, 2018</study_first_posted>
  <last_update_submitted>February 26, 2019</last_update_submitted>
  <last_update_submitted_qc>February 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 27, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nociceptive stimulation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

